STOCK TITAN
  1. Home
  2. News
  3. CASI

CASI Pharmaceuticals Inc - CASI STOCK NEWS

Welcome to our dedicated news page for CASI Pharmaceuticals (Ticker: CASI), a resource for investors and traders seeking the latest updates and insights on CASI Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CASI Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CASI Pharmaceuticals's position in the market.

News
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
Rhea-AI Summary
CASI Pharmaceuticals, Inc. reports a material development in its dispute with Juventas, disclosed in a Form 6-K filing. The company focuses on developing and commercializing innovative therapeutics and pharmaceutical products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
News
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS
Rhea-AI Summary
CASI Pharmaceuticals, Inc. reported fourth quarter 2023 revenue of $6.9 million, 33% lower than 2022, with full-year revenue of $34 million, an 11% decrease. Key highlights include the approval of Inaticabtagene Autoleucel and advancements in pipeline development. Despite positive developments, revenue decline and ongoing arbitration proceedings with Juventas pose challenges for CASI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.33%
Tags
earnings
-
News
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
Rhea-AI Summary
CASI Pharmaceuticals and BioInvent International announce positive preliminary efficacy data for BI-1206 in combination with rituximab for patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
clinical trial
News
CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA
Rhea-AI Summary
CASI Pharmaceuticals administers first dose of FOLOTYN to a patient in China, a significant step in addressing peripheral T-cell lymphoma. Pralatrexate shows promising results with an overall response rate of 52% and a median progression-free survival of 4.8 months in Chinese study. CEO Dr. Wei-Wu He expresses enthusiasm for advancing patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
none
-
News
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES
Rhea-AI Summary
CASI Pharmaceuticals, Inc. (Nasdaq: CASI) reported Q3 2023 financial results, including a 13.5% decrease in sales revenue. The company's partner Juventas received approval for Inaticabtagene Autoleucel in China, marking the first commercialized cell therapy for B-ALL in the country.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
earnings
-
News
CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA
Rhea-AI Summary
CASI Pharmaceuticals Inc. (Nasdaq: CASI) announces market approval for Juventas Cell Therapy Ltd.'s Inaticabtagene Autoleucel (CNCT 19) by China's NMPA for treating r/r B-ALL. The CD19 CAR-T cell therapy product has shown high efficacy and safety in clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
News
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
earnings
-
News
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals
Rhea-AI Summary
CASI Pharmaceuticals, Inc. has announced an Assignment Agreement with Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. for the commercialization of FOLOTYN® in China. FOLOTYN® is a drug approved for the treatment of relapsed or refractory peripheral T-cell lymphoma. CASI will assume the rights and obligations for the commercialization of FOLOTYN® in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
none
-
News
Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets
Rhea-AI Summary
CASI Pharmaceuticals has acquired global rights to CB-5339, a clinical-stage VCP/p97 inhibitor, while Eikon Therapeutics has acquired Cleave Therapeutics' pre-clinical assets. CB-5339 has shown promise in a Phase 1 clinical trial for acute myeloid leukemia and myelodysplastic syndrome. CASI plans to develop CB-5339 for multiple myeloma in China, while Eikon aims to leverage Cleave's preclinical assets to address novel targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
acquisition
News
CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339
Rhea-AI Summary
CASI Pharmaceuticals, Inc. (Nasdaq: CASI) announced the execution of an Assignment Agreement with Cleave Therapeutics, Inc. to obtain all rights and global intellectual property related to CB-5339, a novel VCP/p97 inhibitor. The company will also assume responsibility for the US CB-5339 Investigational New Drug application. CB-5339 is an oral, second-generation, small molecule valosin-containing protein (VCP)/p97 inhibitor, designed to disrupt protein homeostasis, DNA damage response, and other cellular stress pathways. In a Phase 1 clinical trial, the drug was well tolerated in 55 patients and demonstrated signs of clinical activity. Two patients remain on CB-5339 under compassionate use protocols at two leading US cancer centers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
acquisition
Stock CASI logo
CASI Pharmaceuticals Inc

Nasdaq:CASI

CASI Rankings

#4956 Ranked by Market Cap
#174 Ranked by Stock Gains
N/A Ranked by Dividends

CASI Stock Data

34.84M
5.44M
47.13%
2.07%
0.61%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Rockville

About CASI

casi pharmaceuticals, inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in china, the united states, and internationally. the company's product pipeline includes evomela, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. its product pipeline also comprise cnct19, an autologous cd19 car-t investigative product for the treatment of patients with b-cell acute lymphoblastic leukemia (b-all) and b-cell non-hodgkin lymphoma; cid-103, an anti-cd38 monoclonal antibody being for the treatment of patients with multiple myeloma; zevalin, a cd20-directed radiotherapeutic antibody, to treat patients with nhl; and thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. in addition, the company of